XML 56 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill [Table Text Block]
The following table represents the changes in goodwill:
 
December 31,
 
2014
 
2013
Beginning balance
$
398,905

 
$
398,941

Foreign currency translation adjustments and other
(2,676
)
 
(344
)
Goodwill acquired during the year
9,293

 
308

Ending balance
$
405,522

 
$
398,905

The following table represents the changes in goodwill by segment:
 
Energy &
Chemicals
 
Distribution & Storage
 
BioMedical
 
Total
Balance at January 1, 2013
$
83,215

 
$
158,789

 
$
156,937

 
$
398,941

Foreign currency translation adjustments and other
—

 
957

 
(1,301
)
 
(344
)
Goodwill acquired during the year
—

 
308

 
—

 
308

Balance at December 31, 2013
83,215

 
160,054

 
155,636

 
398,905

Foreign currency translation adjustments and other
130

 
(2,806
)
 
—

 
(2,676
)
Goodwill acquired during the year
9,293

 
—

 
—

 
9,293

Balance at December 31, 2014
$
92,638

 
$
157,248

 
$
155,636

 
$
405,522
Schedule Of Finite Lived And Indefinite Lived Intangible Assets [Table Text Block]
The following table displays the gross carrying amount and accumulated amortization for finite-lived intangible assets and indefinite-lived intangible assets (exclusive of goodwill)(1):
  
December 31, 2014
 
December 31, 2013
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Gross
Carrying
Amount
 
Accumulated
Amortization
Finite-lived intangible assets:
 
 
 
 
 
 
 
Unpatented technology
$
35,933

 
$
(6,979
)
 
$
43,133

 
$
(11,776
)
Patents
7,809

 
(6,213
)
 
7,904

 
(5,397
)
Trademarks and trade names
8,981

 
(6,206
)
 
9,244

 
(4,525
)
Non-compete agreements
421

 
(88
)
 
—

 
—

Customer relations
157,533

 
(85,187
)
 
159,143

 
(73,460
)
Total finite-lived intangible assets
$
210,677

 
$
(104,673
)
 
$
219,424

 
$
(95,158
)
Indefinite-lived intangible assets:
 
 
 
 
 
 
 
Trademarks and trade names
$
47,662

 
 
 
$
47,876

 
 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
The Company estimates amortization expense to be recognized during the next five years as follows:
For the Year Ending December 31,
 
2015
$
16,200

2016
14,300

2017
13,400

2018
12,700

2019
12,500

The Company recorded an impairment loss of $3,070 during 2012 resulting in the elimination of in-process research & development (“IPR&D”) indefinite-lived intangible assets related to a prior BioMedical segment acquisition. Higher forecasted costs and project delays represented impairment indicators requiring the Company to re-evaluate the fair value of the IPR&D indefinite-lived intangible assets. The Company conducted an impairment test based on the multi-period excess earnings valuation method which determines fair value based on the present value of the prospective net cash flow attributable to the intangible asset (Level 3 in the fair value hierarchy).  The Company determined that the fair value of the IPR&D indefinite-lived intangible assets was zero and impaired the intangible assets by a value equal to their carrying amount.